BRPI0921044A2 - composto heterocíclico de acenafto, composto de inclusão de ciclodextrina do composto heterocíclico de acenafto, complexo de ciclodextrina do composto heterocíclico de acenafto, uso do composto heterocíclico de acenafto, uso do composto de inclusão de ciclodextrina do composto heterocíclico de acenafto e uso do complexo de ciclodextrina - Google Patents

composto heterocíclico de acenafto, composto de inclusão de ciclodextrina do composto heterocíclico de acenafto, complexo de ciclodextrina do composto heterocíclico de acenafto, uso do composto heterocíclico de acenafto, uso do composto de inclusão de ciclodextrina do composto heterocíclico de acenafto e uso do complexo de ciclodextrina

Info

Publication number
BRPI0921044A2
BRPI0921044A2 BRPI0921044A BRPI0921044A BRPI0921044A2 BR PI0921044 A2 BRPI0921044 A2 BR PI0921044A2 BR PI0921044 A BRPI0921044 A BR PI0921044A BR PI0921044 A BRPI0921044 A BR PI0921044A BR PI0921044 A2 BRPI0921044 A2 BR PI0921044A2
Authority
BR
Brazil
Prior art keywords
compound
acenapht
heterocyclic
cyclodextrin
complex
Prior art date
Application number
BRPI0921044A
Other languages
English (en)
Inventor
Xie Feibo
Wu Guiye
Song Ting
Zhang Zhichao
Original Assignee
Univ Dalian Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dalian Tech filed Critical Univ Dalian Tech
Publication of BRPI0921044A2 publication Critical patent/BRPI0921044A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
BRPI0921044A 2008-11-11 2009-10-25 composto heterocíclico de acenafto, composto de inclusão de ciclodextrina do composto heterocíclico de acenafto, complexo de ciclodextrina do composto heterocíclico de acenafto, uso do composto heterocíclico de acenafto, uso do composto de inclusão de ciclodextrina do composto heterocíclico de acenafto e uso do complexo de ciclodextrina BRPI0921044A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA2008102287462A CN101423491A (zh) 2008-11-11 2008-11-11 苊并杂环类化合物及其在制备BH3类似物类Bcl-2家族蛋白抑制剂中的应用
PCT/CN2009/074602 WO2010054575A1 (zh) 2008-11-11 2009-10-25 苊并杂环类化合物、其环糊精包合物和环糊精配结物以及它们在制备BH3类似物Bcl-2家族蛋白抑制剂中的应用

Publications (1)

Publication Number Publication Date
BRPI0921044A2 true BRPI0921044A2 (pt) 2019-09-24

Family

ID=40614399

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921044A BRPI0921044A2 (pt) 2008-11-11 2009-10-25 composto heterocíclico de acenafto, composto de inclusão de ciclodextrina do composto heterocíclico de acenafto, complexo de ciclodextrina do composto heterocíclico de acenafto, uso do composto heterocíclico de acenafto, uso do composto de inclusão de ciclodextrina do composto heterocíclico de acenafto e uso do complexo de ciclodextrina

Country Status (13)

Country Link
US (1) US20110251188A1 (pt)
EP (1) EP2366701A1 (pt)
JP (1) JP2012508194A (pt)
KR (1) KR20110086848A (pt)
CN (2) CN101423491A (pt)
AU (1) AU2009316152A1 (pt)
BR (1) BRPI0921044A2 (pt)
CA (1) CA2742856A1 (pt)
IL (1) IL212393A0 (pt)
MX (1) MX2011004643A (pt)
RU (1) RU2011118591A (pt)
WO (1) WO2010054575A1 (pt)
ZA (1) ZA201103355B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101423491A (zh) * 2008-11-11 2009-05-06 大连理工大学 苊并杂环类化合物及其在制备BH3类似物类Bcl-2家族蛋白抑制剂中的应用
CN101723907B (zh) * 2009-07-25 2011-09-14 大连理工大学 一类邻二氰基苊并吡嗪化合物及其抗肿瘤应用
CN101633637B (zh) * 2009-08-18 2011-09-28 华东理工大学 8-氧-8H-苊并[1,2-b]吡咯衍生物
WO2012012941A1 (zh) * 2010-07-28 2012-02-02 大连理工大学 Bcl-2家族蛋白抑制剂,其环糊精包合物、配结物及其在制备bcl-2家族蛋白抑制剂中的应用
CN102336700B (zh) * 2010-07-28 2013-11-06 大连理工大学 一类氨基取代苊并杂环类化合物及其应用
WO2012013147A1 (zh) * 2010-07-28 2012-02-02 大连理工大学 苊并杂环类化合物及其应用
CN102321012B (zh) * 2010-07-28 2013-08-21 大连理工大学 一类苊并杂环类化合物及其应用
WO2012100368A1 (zh) * 2011-01-25 2012-08-02 大连理工大学 筛选肿瘤细胞的方法及其用途
CN103435574B (zh) * 2013-08-15 2014-10-29 大连理工大学 一种巯基苯并噻唑取代的苊并杂环类化合物及其应用
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
CN107382862A (zh) * 2017-07-17 2017-11-24 大连理工大学 硫/氧代萘酰亚胺类化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304370C (zh) * 2004-09-15 2007-03-14 大连理工大学 苊并杂环类化合物及其诱导细胞凋亡和抗肿瘤的应用
CN1931840A (zh) * 2006-10-13 2007-03-21 华东理工大学 一类dna靶分子及其诱导细胞凋亡和抗肿瘤的应用
CN101423491A (zh) * 2008-11-11 2009-05-06 大连理工大学 苊并杂环类化合物及其在制备BH3类似物类Bcl-2家族蛋白抑制剂中的应用

Also Published As

Publication number Publication date
KR20110086848A (ko) 2011-08-01
MX2011004643A (es) 2011-10-28
EP2366701A1 (en) 2011-09-21
US20110251188A1 (en) 2011-10-13
ZA201103355B (en) 2012-01-25
JP2012508194A (ja) 2012-04-05
IL212393A0 (en) 2011-06-30
CN101928243B (zh) 2012-09-05
WO2010054575A1 (zh) 2010-05-20
RU2011118591A (ru) 2012-12-20
AU2009316152A1 (en) 2010-05-20
CA2742856A1 (en) 2010-05-20
CN101928243A (zh) 2010-12-29
CN101423491A (zh) 2009-05-06

Similar Documents

Publication Publication Date Title
BRPI0921044A2 (pt) composto heterocíclico de acenafto, composto de inclusão de ciclodextrina do composto heterocíclico de acenafto, complexo de ciclodextrina do composto heterocíclico de acenafto, uso do composto heterocíclico de acenafto, uso do composto de inclusão de ciclodextrina do composto heterocíclico de acenafto e uso do complexo de ciclodextrina
CR20130360A (es) Compuesto heterocíclico y su uso
BR112012002349A2 (pt) composto,e, uso do mesmo
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
BRPI0917535A2 (pt) uso de insulina de ação ultra rápida
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0915134A2 (pt) composto, e, uso de um composto
BRPI0906186A2 (pt) composto e uso de um composto
DK2308877T3 (da) Imidazopyridin-2-on-derivater
BRPI1015315A2 (pt) composto heterocíclico fundido e uso dos mesmos
BRPI0906980A2 (pt) Composição de derivados e maleatados
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0915086A2 (pt) detecção do uso de canabis
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0906352A2 (pt) Derivado de tiazol e uso do mesmo como inibidores de vap-1
DK2275414T3 (da) Cyclopentylacrylamidderivat
BRPI0808172A2 (pt) Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
ATE533761T1 (de) Imidazolidinonderivate
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BRPI1006996A2 (pt) composição, método e uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.